BioSpace News Archive

Drug Development

Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors

Immuneering Corporation today announced positive topline results from the ongoing Phase 1 portion of its Phase 1/2a clinical trial of IMM-1-104 in advanced RAS-mutant solid tumors.

March 14, 2024
·
11 min read
Business

PRECISIO BIOTIX THERAPEUTICS ANNOUNCES COLLABORATION WITH MAYO CLINIC

Precisio Biotix Therapeutics (“Precisio”) today announced it has entered into an agreement with Mayo Clinic.

March 14, 2024
·
3 min read
Business

Benson Hill Reports Solid Full-Year 2023 Financial Results, Strengthens Balance Sheet

Benson Hill, Inc. (NYSE:BHIL, the “Company” or “Benson Hill”), an ag-tech company unlocking the natural genetic diversity of plants, today announced operating and financial results for the year ended December 31, 2023.

March 14, 2024
·
25 min read
Business

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Century Therapeutics, Inc. today reported financial results and business highlights for the full year ended December 31, 2023.

March 14, 2024
·
14 min read
Drug Development

Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

Cybin Inc. today announced a positive End-of-Phase 2 meeting with the FDA for CYB003, its deuterated psilocybin analog for the adjunctive treatment of Major Depressive Disorder (“MDD”).

March 14, 2024
·
10 min read
BioCapital

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

60 Degrees Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has communicated its intention to send any comments regarding the Company’s babesiosis trial within the month of April, 2024, rather than March, 2024 as anticipated by the Company.

March 14, 2024
·
7 min read
Business

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024

Achieve Life Sciences, Inc. today announced it will report its fourth quarter and year-end 2023 financial results and provide an update on the cytisinicline development program on Thursday, March 28, 2024, at 4:30 PM EST.

March 14, 2024
·
4 min read
FDA

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Keros Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for KER-050 for the treatment of anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”).

March 14, 2024
·
4 min read
ZyVersa Therapeutics’ CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024

ZyVersa Therapeutics, Inc. announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will participate in a panel discussion titled “Inflammation Illuminated,” at Benzinga’s Virtual Healthcare Summit 2024.

March 14, 2024
·
5 min read
Drug Development

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).

March 14, 2024
·
3 min read